
What is Usha Vance's net worth? Know about US Second Lady's career, properties, assets
JD Vance, the vice president of the United States, has become a key member of the leadership team in just four months of the Donald Trump administration. Vance, along with his Indian origin wife Usha Chilukuri Vance and three kids, has arrived in India for formal discussions with Prime Minister Narendra Modi amid escalating tensions over high tariffs. This is Usha's first official visit to the nation since the inauguration of her husband as the US VP.
The Vances' four-day trip includes visits to Jaipur and Agra and formal meetings in Delhi. The itinerary also includes the Taj Mahal.
Usha's family descends from Vadluru village, which is located in Andhra Pradesh's former West Godavari district. She was born in the United States, but her parents left this village and moved abroad.
Indian-American Usha has previously stated that her parents are Hindu and that she is originally from Andhra Pradesh.
She has supported Vance during his community service and political career. She received a BA in history from Yale University and an MPhil in early modern history from Cambridge University, where she was a Gates Scholar.
Her father is a mechanical engineer, and her mother is a molecular scientist.
Both Usha Vance's grandfather and father were Indian Institute of Technology (IIT) faculty or students.
Usha Vance started a career in law after graduating from Yale with a Juris Doctor. In 2014, she served as a clerk for Brett Kavanaugh, a Supreme Court justice who was then a Circuit Judge in the District of Columbia. In 2017, she continued in the same position with Chief Justice John Roberts of the Supreme Court.
Vance, who is a member of the DC Bar, worked at California-based firm Munger Tolles & Olson, where she defended clients at the firm who had ties to the University of California and The Walt Disney Company.
Also Read: JD and Usha Vance's kids steal the show in traditional Indian wear after landing in Delhi
While Usha Vance's net worth is unknown, she and her husband are the owners of two properties.
In 2014, shortly after their marriage, they purchased their initial residence in Washington, D.C., east of the Capitol building. Forbes claims that they bought the property at USD 590,000, and that they had to borrow somewhat more than USD 600,000 to cover the expense. The estimated current value of the house is USD 850,000. They have no debts other than the remaining USD 480,000 from the borrowings.
In 2018, they purchased a second residence. The residence, which is located East Walnut Hills, Cincinnati, is said to have cost the couple USD 1.4 million.
JD Vance's Forbes profile suggests he is worth approximately USD 10 million. His most of the wealth comes from his venture company, Narya, which he founded in 2019.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
16 minutes ago
- Economic Times
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. ADVERTISEMENT According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares, amounting to a 10.20 per cent stake in Indegene. The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). ADVERTISEMENT Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. ADVERTISEMENT In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions. (You can now subscribe to our ETMarkets WhatsApp channel)


Time of India
18 minutes ago
- Time of India
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares , amounting to a 10.20 per cent stake in Indegene. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like コンピュータでゲームをするのが好きなら、この新しいアドベンチャーゲームは必ずプレイすべきです。 アドベンチャーゲーム ゲームをプレイ Undo The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0.00% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Live Events Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions.


Indian Express
29 minutes ago
- Indian Express
A father-son legacy of Padma honors and pioneering scientific research
Written by Siddhi Patil, Dr Chetan Eknath Chitnis, a globally renowned Indian scientist, has dedicated his life to combating malaria, a persistent global health challenge claiming countless lives annually. His groundbreaking work in malaria vaccine development has earned him the prestigious Padma Shri this year, alongside awards like the Shanti Swarup Bhatnagar Award and the Infosys Prize. Remarkably, Dr. Chitnis shares a rare distinction with his father, Eknath Vasant Chitnis, a Padma Bhushan recipient (1985) and a founding member of the Indian Space Research Organisation (ISRO). This rare father-son duo's Padma honors reflect a deep family legacy of scientific excellence, with both making transformative contributions to their respective fields. Dr. Chitnis's journey in medical research is deeply rooted in his upbringing. His father, a distinguished space scientist and former director of ISRO's Space Application Centre, instilled a passion for dedicated work. 'My father taught me that true commitment means loving what you do, no matter the hours,' Dr. Chitnis recalls. While he initially pursued physics, inspired by his father's rigor, it was his mother, a biochemist focused on cancer research, who steered him toward biology. This pivot led him to lead the Malaria Parasite Biology and Vaccines Unit at Institut Pasteur in Paris, where he drives innovative vaccine research to curb malaria's devastating impact. Pune holds a special place in Dr. Chitnis's heart. Childhood summers spent at his grandparents' home in Deccan Gymkhana, exploring nearby hills with cousins, evoke memories of a serene, green Pune. His parents' decision to settle in the city post-retirement deepened his connection. Today, as Pune evolves into a bustling hub of innovation, Dr. Chitnis is eager to engage with its academic and research communities, blending personal nostalgia with professional aspirations. From IIT Bombay to UC Berkeley, the National Institutes of Health, and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi, Dr. Chitnis's career spans continents. His work at ICGEB, supported by robust government backing, laid the foundation for his current efforts in Paris. A significant breakthrough came during the COVID-19 pandemic when delayed vaccine trials at Oxford revealed that a 14-month gap between doses reduced malaria parasite growth—an unexpected finding inspired by similar COVID-19 vaccine insights. This discovery, coupled with advancements in mRNA technology, fuels his cautious optimism for future malaria solutions. The Padma Shri holds deep significance for Dr. Chitnis. 'Being recognised by my homeland, even after a decade abroad, is humbling,' he says. He views the award as a tribute to his team's collective efforts and a call to continue serving society.